Identification and Characterization of Antigenically Advanced Variants to Accelerate and Improve Influenza Vaccine Development

The Centers for Disease Control and Prevention is forecasting a contract opportunity titled Identification and Characterization of Antigenically Advanced Variants to Accelerate and Improve Influenza Vaccine Development, with a posted date of May 25, 2026. This activity falls under NAICS code 541714, indicating it relates to research and development in the physical, engineering, and life sciences. The project aims to advance influenza vaccine development by identifying and characterizing emerging viral variants with significant antigenic properties, enabling more timely and effective vaccine updates. The performance location is not specified, and the contract is not set aside for any particular small business category. Point of contact for the program is Charmaine McKenzie via buo4@cdc.gov, while the Contracting Officer position remains undetermined. The forecast is issued through the HHS OSDBU portal, suggesting it is preliminary information for industry awareness ahead of a formal solicitation. No solicitation number is provided yet, and the exact funding amount, duration, or application deadlines are not disclosed in this forecast. Interested parties should monitor updates through the provided UI link for future formal notices and submission requirements.